



ASSURING THE SAFETY, QUALITY AND EFFICACY  
OF VETERINARY MEDICINES

United Kingdom  
Veterinary Medicines Directorate  
Woodham Lane  
New Haw  
Addlestone  
Surrey  
KT15 3LS

(Reference Member State)

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY  
MEDICINAL PRODUCT

Cephacare flavour 250 mg tablets for dogs

**PuAR correct as of 16/04/2018 when RMS was transferred  
to IE. Please contact the RMS for future updates.**

## **MODULE 1**

### **PRODUCT SUMMARY**

EU Procedure number	UK/V/0251/002/DC
Name, strength and pharmaceutical form	Cephacare flavour 250 mg tablets for dogs
Applicant	Animalcare Ltd Common Road Dunnington York YO19 5RU, UK
Active substance	Cefalexin as cefalexin monohydrate
ATC Vetcode	QJ01DB01
Target species	Dogs
Indication for use	Treatment of infections of the respiratory tract, gastro-intestinal tract, urogenital tract, the skin and localised infections in soft tissue caused by bacteria sensitive to cefalexin.

## **MODULE 2**

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies (veterinary) (HMA(v)) website ([www.hma.eu](http://www.hma.eu)).

## **MODULE 3**

### **PUBLIC ASSESSMENT REPORT**

Legal basis of original application	Generic application in accordance with Article 13 (1) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	01 October 2008
Date product first authorised in the Reference Member State (MRP only)	N/A
Concerned Member States for original procedure	Austria Belgium France Germany Ireland Luxembourg Portugal Spain.

#### **I. SCIENTIFIC OVERVIEW**

The product is a beige, round biconvex tablet for oral administration in dogs. It contains 250 mg Cefalexin as cefalexin monohydrate. Cefalexin has a broad spectrum activity against a wide range of bacteria. The recommended dose rate is 15 mg/kg bodyweight twice daily for 5 days.

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released on the market. It has been shown that the product can be safely used in the target species. The slight reactions observed are indicated in the SPC. The product is safe for the user and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC. The overall risk/benefit analysis is in favour of granting a marketing authorisation.

This is a generic application based on bioequivalence to Ceporex Vet 250, 250 mg tablets. This product was first authorised in the UK on 16th July 1991.

## II. QUALITY ASPECTS

### **A. Composition**

The product contains 250 mg of the active substance Cefalexin as Cefalexin Monohydrate and the excipients Lactose Monohydrate, Potato Starch, Magnesium Stearate and Beef Flavour.

The container/closure system comprises a heat sealed PVC/aluminium foil blister containing 10 tablets. Either 10 or 25 blister strips are then packed into a cardboard carton. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation and absence of preservative are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

### **B. Method of Preparation of the Product**

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

### **C. Control of Starting Materials**

The active substance is Cefalexin, an established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The active substance is supplied in accordance with a European Pharmacopoeia Certificate of Suitability.

Excipients, apart from the Beef Flavour, are the subject of monographs in the European Pharmacopoeia. Compliance with the requirements of the pharmacopoeia was therefore applied as the specification for each of these ingredients. The Beef Flavour, complies fully with Directive 88/388/EC concerning labelling of foods flavours and meets an in-house specification.

### **D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies**

Scientific data have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

**E. Control on intermediate products**

There are no intermediate products.

**F. Control Tests on the Finished Product**

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production sites have been provided demonstrating compliance with the specification.

**G. Stability**

Stability data on Cefalexin have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

**H. Genetically Modified Organisms**

Not applicable

**J. Other Information**

**Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years

Return any ½ tablet to the blister pack and use within 24 hours

**Special precautions for storage**

Do not store above 25°C

Store in a dry place

Keep the blister in the outer carton

**III. SAFETY AND RESIDUES ASSESSMENT (PHARMACOTOXICOLOGICAL)**

**III.A Safety Testing**

**Pharmacological Studies**

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmacological tests are not required.

The pharmacological aspects of this product are identical to the reference product Ceporex Vet 250, 250 mg tablets.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users and the environment.

### **Toxicological Studies**

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this product are identical to the reference product Ceporex Vet 250, 250 mg tablets.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users and the environment.

### **User Safety**

The applicant has not submitted a user risk assessment for the proposed products which has been justified on the basis of the applications being for generic products and that the use is considered identical to that of the reference products. The user warnings proposed are the same as the reference products as given below:

- Penicillins and cephalosporins may cause sensitisation (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillin may lead to cross-reactions to cephalosporin and vice versa. Allergic reactions to these substances may occasionally be serious.
- Do not handle this product if you know you are sensitised to or if you have been advised not to be in contact with such substances.
- Handle this product with great care to avoid exposure, taking all recommended precautions.
- If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty breathing are more serious symptoms and require urgent medical attention.
- In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
- Wash hands after use.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

### **Ecotoxicity**

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that further assessment was not required. Warnings and precautions as listed on the product literature are adequate to ensure safety to the environment when the product is used as directed.

## **IV CLINICAL ASSESSMENT (EFFICACY)**

### ***IV.A Pre-Clinical Studies***

#### ***Pharmacology***

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

#### ***Tolerance in the Target Species of Animals***

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, tolerance studies are not required. The safety claims for this product are equivalent to those of the reference product.

#### ***Resistance***

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, resistance data are not required.

### ***IV.B Clinical Studies***

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

## **V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT**

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.



## **MODULE 4**

### **POST-AUTHORISATION ASSESSMENTS**

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

[www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

[www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed)